Quest PharmaTech has got clearance from FDA to initiate US sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.
The aim of the trial will be to know whether closed oregovomab in relation with front-line chemotherapy will generate the same or an improved immunity and clinical response.
Out of the three participating U.S. Centres in the trial two have got needed approvals as the third centre awaits institutional review board (IRB) approval.
Quest pharma Chairman Christopher Nicodemus said,"A systemic study of combinatorial immunisation strategies such as the current trial with evidence based preliminary observations has the potential of revolutionising cancer therapy and may lead to important commercial applications."
Quest CEO Madi R. Madiyalakan said,"We are pleased with the interest from the U.S. centres to participate in this important clinical trial. The additional centres will not only speed up patient enrolment for the study, but will raise the profile and awareness of Quest’s lead immunotherapy product in the ovarian cancer community in North America."